SPONSOR

AstraZeneca

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 2, Phase 3, Phase 1

Conditions studied: Hypertension Chronic Obstructive Pulmonary Disease (COPD)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Non-Small-Cell Lung Advanced or Metastatic Non-small Cell Lung Cancer Locally Advanced (Inoperable) or Metastatic Breast Cancer Primary Hyperaldosteronism Lymphoma Non-Hodgkin Lymphoma

AstraZeneca is a British-Swedish multinational biopharmaceutical company with one of the industry's most active clinical pipelines in oncology, cardiovascular-renal-metabolic disease, respiratory and immunology, and rare diseases. Founded in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca today invests approximately $9–10 billion annually in R&D. Their trial portfolio is notable for several landmark programs including the DAPA-HF and DAPA-CKD trials (dapagliflozin), the ADAURA and LAURA trials (osimertinib for lung cancer), and the AstraZeneca-Oxford COVID-19 vaccine development.

AstraZeneca's oncology unit — operating as AstraZeneca Oncology — maintains deep expertise in targeted therapy for EGFR-mutated non-small cell lung cancer, HER2-targeted therapies (trastuzumab deruxtecan, developed with Daiichi Sankyo), PARP inhibitors for ovarian and breast cancer (olaparib), and immuno-oncology through the PD-L1 inhibitor durvalumab. The cardiovascular and metabolic portfolio includes one of the most extensive SGLT2 inhibitor trial programs ever conducted, spanning heart failure, chronic kidney disease, and type 2 diabetes across thousands of participants in dozens of countries.

AstraZeneca's clinical trials are conducted at leading academic and community research centers worldwide. The company has made public commitments to diversity in clinical research and has implemented specific protocols to increase enrollment from historically underrepresented groups. AstraZeneca participates in pre-competitive partnerships through organizations such as the Innovative Medicines Initiative (IMI) and TransCelerate BioPharma.

Frequently Asked Questions — AstraZeneca

What is AstraZeneca best known for in clinical research?

AstraZeneca is best known clinically for three major areas: (1) lung cancer — their EGFR inhibitor osimertinib (Tagrisso) demonstrated unprecedented survival improvements in adjuvant NSCLC and is the subject of ongoing trials in earlier disease stages and combination settings; (2) heart failure and kidney disease — dapagliflozin (Farxiga) has been shown in Phase 3 trials to significantly reduce hospitalization and mortality across both heart failure subtypes and in CKD independent of diabetes; and (3) PD-L1 inhibition — durvalumab (Imfinzi) has received approvals in multiple cancer indications and is under investigation in dozens of additional combinations.

Does AstraZeneca run trials outside of cancer?

Yes. While oncology represents the largest share of AstraZeneca's current trial portfolio, the company has equally robust programs in cardiovascular, renal, and metabolic disease (CVRM), respiratory and immunology, and rare diseases. Their CVRM trials include investigations of SGLT2 inhibitors, GLP-1/GIP agonists (in collaboration with partners), and novel mechanisms in heart failure. The respiratory portfolio covers severe asthma (benralizumab, tezepelumab), COPD, and interstitial lung disease. Rare disease trials focus on conditions with high unmet medical need including complement-mediated diseases and severe respiratory disorders.

How does AstraZeneca approach diversity and inclusion in clinical trials?

AstraZeneca has a published global diversity and inclusion framework for clinical trials that sets targets for enrollment of women, patients from racial and ethnic minority groups, and older adults across all Phase 2 and Phase 3 studies. The company works with community organizations and patient advocacy groups to identify and address barriers to participation — including transportation, language, and lack of awareness — particularly for oncology and rare disease trials where underrepresentation has historically been greatest. These commitments are reported annually in AstraZeneca's Global Sustainability Report.

AstraZeneca

Frequently Asked Questions — AstraZeneca

Clinical Trials by AstraZeneca

Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Study of Patient With Frequent Exacerbations in Moscow

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

The Anifrolumab PRIM Program

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

The Eplontersen Pregnancy and Lactation Outcomes Study

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

A Prospecitve Multicenter, Observational Registry Study

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

DESTINY-PANTUMOUR04

Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

REBECCA Real-world Early BrEast CanCer mAnagement